Volanesorsen
Waylivra (volanesorsen) is an oligonucleotide pharmaceutical. Volanesorsen was first approved as Waylivra on 2019-05-03. It has been approved in Europe to treat hyperlipoproteinemia type i.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
27 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hyperlipoproteinemia type i | D008072 | Orphanet_411 | E78.3 | — | — | 1 | — | 1 | 2 |
| Hyperlipoproteinemia type v | D006954 | Orphanet_70470 | E78.3 | — | — | 1 | — | — | 1 |
| Familial partial lipodystrophy | D052496 | — | 1 | 1 | — | — | 1 | ||
| Hypertriglyceridemia | D015228 | EFO_0004211 | — | — | 1 | — | — | 1 | |
| Adenomatous polyposis coli | D011125 | — | — | 1 | — | — | 1 | ||
| Crohn disease | D003424 | EFO_0000384 | K50 | — | — | 1 | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 5 | — | — | — | — | 5 | ||
| Infections | D007239 | EFO_0000544 | 1 | — | — | — | — | 1 | |
| Cardiovascular abnormalities | D018376 | EFO_0003848 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | — | — | — | 1 | 1 |
| Periodontitis | D010518 | EFO_0000649 | K05.3 | — | — | — | — | 1 | 1 |
| Phenylketonurias | D010661 | E70.0 | — | — | — | — | 1 | 1 | |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | — | 1 | 1 |
| Short bowel syndrome | D012778 | — | — | — | — | 1 | 1 | ||
| Gastrointestinal diseases | D005767 | — | — | — | — | 1 | 1 | ||
| Milk hypersensitivity | D016269 | EFO_0007369 | — | — | — | — | 1 | 1 | |
| Gastroenteritis | D005759 | EFO_1001463 | K52.9 | — | — | — | — | 1 | 1 |
| Dry eye syndromes | D015352 | H04.12 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | VOLANESORSEN |
| INN | volanesorsen |
| Description | Volanesorsen, sold under the brand name Waylivra, is a triglyceride-reducing drug. It is a second-generation 2'-O-methoxyethyl (2'-MOE) chimeric antisense therapeutic oligonucleotide (ASO) that targets the messenger RNA for apolipoprotein C3 (apo-CIII).
|
| Classification | Oligonucleotide |
| Drug class | antisense oligonucleotides |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL3544994 |
| ChEBI ID | — |
| PubChem CID | 122409770 |
| DrugBank | DB15067 |
| UNII ID | 2O4BE0K238 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Waylivra - Ionis Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 369 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
233 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more